|1.||Cavazos-Rocha, Norma: 2 articles (11/2014 - 01/2008)|
|2.||Vera-Cabrera, Lucio: 2 articles (11/2014 - 01/2008)|
|3.||Salazar-Cavazos, María de la Luz: 1 article (11/2014)|
|4.||Carmona-Alvarado, Idalia: 1 article (11/2014)|
|5.||Waksman-de-Torres, Noemí: 1 article (11/2014)|
|6.||Marchillo, Karen: 1 article (11/2012)|
|7.||Lepak, Alexander J: 1 article (11/2012)|
|8.||Craig, William A: 1 article (11/2012)|
|9.||Andes, David R: 1 article (11/2012)|
|10.||Pichereau, Solen: 1 article (11/2012)|
02/01/2011 - "Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections."
07/01/2011 - "aureus infection using MRSA ATCC 33591 to identify the dose and schedule of administration of TR-701/700 that was linked with optimized antimicrobial effect. "
07/01/2011 - "In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model."
12/01/2011 - "The Trius Therapeutics compound tedizolid phosphate (formerly known as torezolid phosphate, TR-701, DA-7218), the most advanced, is in phase 3 clinical trials for acute bacterial skin and skin structure infections. "
09/01/2012 - "The in vitro activity of tedizolid (previously known as torezolid, TR-700) against penicillin-resistant Streptococcus pneumoniae (PRSP) clinical isolates and the in vivo efficacy of tedizolid phosphate (torezolid phosphate, TR-701) in murine models of PRSP systemic infection and penicillin-susceptible S. "
01/01/2008 - "Efficacy of DA-7218, a new oxazolidinone prodrug, in the treatment of experimental actinomycetoma produced by Nocardia brasiliensis."
01/01/2008 - "At the end of treatment, there was a statistically significant difference between the three drug receiving groups (25, 12.5 and 5 mg/kg) and the control group(saline solution) (p=0.001), proving that DA-7218 is effective for the treatment of experimental murine actinomycetoma. "
11/01/2014 - "A chromatographic method was implemented and validated for the simultaneous determination of antimicrobials proposed for the treatment of mycetoma: three fluoroquinolones: ciprofloxacin, moxifloxacin and sparfloxacin; two oxazolidinones: DA-7157 (DA2; torezolid) and its prodrug DA-7218 (DA1). "
|4.||Body Weight (Weight, Body)
|2.||3- (3- fluoro- 4- (6- (2- methyl- 2H- tetrazol- 5- yl)pyridin- 3- yl)phenyl)- 5- hydroxymethyloxazolidin- 2- one
|3.||Sodium Chloride (Saline Solution)
|6.||Oxazolidinones (2 Oxazolidone)